How radical is radical cure? Site-specific biases in phase-III clinical trials underestimate

the effect of radical cure against *Plasmodium vivax* hypnozoites

John H. Huber[1*], Cristian Koepfli[1], Guido España[1], Narimane Nekkab[2], Michael T. White[2],

T. Alex Perkins[1]

[1]Department of Biological Sciences & Eck Institute for Global Health, University of Notre

Dame, Notre Dame, IN, USA

[2]Unité Malaria: Parasites et Hôtes, Département Parasites et Insectes Vecteur, Institut Pasteur,

Paris, FRA

Corresponding Author: jhuber3@nd.edu (JHH)

ABSTRACT

Background: *Plasmodium vivax* relapses caused by reactivating hypnozoites are a major barrier

for elimination and control of this form of malaria. Radical cure is a form of therapy capable of

addressing this problem. Recent clinical trials of radical cure have yielded efficacy estimates

ranging from 65% to 94%, with substantial variation across trial sites. We performed an analysis

of simulated trial data using a transmission model to demonstrate that variation in efficacy

estimates across trial sites can arise from differences in the conditions under which trials are

conducted.

Methods and Findings: Our analysis revealed that differences in transmission intensity,

heterogeneous exposure, and relapse rate can yield efficacy estimates ranging as wide as 11-

82%, despite simulating trial data under the uniform assumption that treatment had a 75% chance

of clearing hypnozoites. A longer duration of prophylaxis leads to a greater measured efficacy,

particularly at higher transmission intensities, making the comparison of the protection of

different radical cure treatment regimens against relapse more challenging. We show that vector

control and parasite genotyping offer two potential means to yield more standardized efficacy

estimates that better reflect protection against relapse.

Conclusions: We predict that site-specific biases are likely to contribute to variation in efficacy

estimates both within and across phase-III clinical trials. Future clinical trials can reduce site-

specific biases by conducting trials in low-transmission settings where reinfections from

mosquito biting are less common, by preventing reinfections using vector control measures, or

by identifying and excluding reinfections that occur during follow-up using parasite genotyping

methods.

INTRODUCTION

Plasmodium vivax is the most geographically widespread cause of human malaria, and its burden

in 2017 was estimated at 14.3 million clinical cases globally (1). Control of *P. vivax* is

challenging due to a unique life stage of the parasite, known as the hypnozoite, which latently

infects the livers of individuals with recent *P. vivax* blood-stage infections (2). Hypnozoites

activate to cause successive relapsing infections following the initial blood-stage infection, and

relapses comprise an estimated 79 – 96% of all *P. vivax* infections (3,4). The prevention of

relapses is therefore an ongoing priority for *P. vivax* control (5), and clearance of hypnozoites

can be achieved through radical cure treatment with an 8-aminoquinoline, such as primaquine

(PQ) or tafenoquine (TFQ).

Recent phase-III clinical trials for PQ and TFQ have been conducted in Latin America,

sub-Saharan Africa, and Southeast Asia (6–9). The DETECTIVE trial estimated that the

recurrence-free efficacies of PQ and TFQ were 74% and 70%, respectively (6), suggesting a

large potential impact of radical cure as a first-line *P. vivax* treatment (10). However, each trial

noted substantial geographical variation in efficacy estimates. Although potentially reflective of

differences in hypnozoite clearance with 8-aminoquinoline treatment among the distinct trial

populations (11), the geographical variation in efficacy may have instead been attributable to

features of each transmission setting, which would bias our efficacy estimates and limit the

interpretability of trial results when evaluating the extent to which radical cure prevents relapse.

The primary endpoint used in recent phase-III clinical trials is freedom from *P. vivax*

recurrent infection (6–8), which encompasses relapses caused by hypnozoite activation,

reinfections caused by mosquito biting, and recrudescences caused by blood-stage therapeutic

failure (12). Only relapses caused by hypnozoite batches (i.e., a group of hypnozoites that

derives from one infectious mosquito bite) present prior to treatment directly reflect the extent to

which 8-aminoquinoline treatment prevents relapse, or the hypnozoite batch clearance

probability (hereafter, clearance probability) (Fig. 1). Because there remains no reliable way to

distinguish these relapses from all other recurrent infections using epidemiological data alone,

efficacy against recurrent infection is not equal to efficacy against relapse, and the measured

efficacy will likely vary depending upon the site in which the trial is conducted. Obtaining

standardized estimates of the effect of each 8-aminoquinoline against hypnozoite batches will

therefore depend upon the proportion of recurrent infections identified during follow-up that are

relapses caused by hypnozoite batches acquired prior to 8-aminoquinoline treatment.

An incongruence between the primary endpoint and the effect that the clinical trial

intends to measure has previously been noted as a source of bias in measuring the therapeutic

cure rates for *P. falciparum* malaria and tuberculosis (13–15). We propose that the magnitude of

this bias could depend upon features of the trial location and the trial design. Although most or

all clinical *P. vivax* patients enrolled in clinical trials are expected to carry hypnozoites, the rates

at which participants experience reinfections and relapses may vary across trial sites due to

transmission intensity, heterogeneous mosquito biting patterns (16), and the relapse phenotype of

the *P. vivax* parasite (17). The number of recorded relapses also depends upon the duration of

follow-up and the duration of prophylaxis provided by the treatment regimen used in the trial.

The extent to which these different features of the trial location and the trial design contribute to

bias in efficacy estimates—and impact our ability to measure the clearance probability—has not

been explored.

Here, we extend an existing individual-based model of *P. vivax* transmission (10,18) to

simulate phase-III clinical trials for radical cure. To maintain consistency with previous trials, we

modeled our phase-III clinical trials after the recent DETECTIVE trials for PQ and TFQ (6–8).

By varying different features of the trial location and trial design, we sought to understand how

site-specific biases in efficacy estimates may arise. We also explored different approaches, such

as the use of vector control and parasite genotyping methods, that could be implemented to

mitigate site-specific biases and standardize estimates of the effect of radical cure against

hypnozoite batches.

Figure 1. Schematic of potential infection outcomes during trial follow-up. *Participants are*
enrolled in the trial and initially harbor hypnozoite batches (colored squares). The colors
represent the genetic identity of each hypnozoite batch. Hypnozoite batches are cleared (unfilled
dotted squares) with 8-aminoquinoline treatment according to the per-hypnozoite batch
probability of clearance. Treatment with an 8-aminoquinoline provides each participant with a
period of prophylaxis during which reinfections (solid line) and relapses (dotted line) are
suppressed. Following prophylaxis, trial participants can experience reinfections and relapses,
and these reinfections and relapses may be detected during the remainder of follow-up. Only
relapses that arise from the activation of hypnozoite batches that were present before 8-
aminoquinoline treatment reflect the per-hypnozoite batch clearance probability.

RESULTS

Effect of Transmission Intensity and Heterogeneity in Biting

We first examined how transmission intensity and the level of heterogeneity in mosquito biting

patterns in the trial location interact to affect efficacy estimates. We varied transmission intensity

by setting the entomological inoculation rate (EIR) from 0.1 to 100 infectious bites per person-

year and varied the level of heterogeneity in mosquito biting by changing the variance in the

distribution of individual-level exposure to mosquito biting.

When exposure to mosquito biting was the same for all trial participants (Fig. 2B), we

observed a downward bias in efficacy estimates that increased with transmission intensity (Fig.

2A). For clinical trials of an 8-aminoquinoline with a clearance probability equal to 0.75, light

microscopy (LM)-detectable recurrence-free efficacies ranged from 0.80 (IQR: 0.79 - 0.82) at an

EIR of 0.1 to 0.35 (0.30 - 0.40) at an EIR of 100. This downward bias in efficacy occurred

because reinfection by mosquito biting, an infection event that does not reflect the clearance

probability, was more frequent at higher EIR. When EIR was 100, 99% (SD: 0.22%) of

participants were reinfected on average by mosquitoes during the 180-day follow-up period,

compared to only 0.73% (SD: 0.18%) at an EIR of 0.1.

At low transmission intensities when reinfection rates were low, our efficacy estimates

exceeded the clearance probability, revealing a positive bias. This positive bias occurred because

we assumed that radical cure completely cleared hypnozoite batches in a subset of trial

participants and did not clear hypnozoite batches in the remainder of trial participants. In trials

measuring time to first recurrent infection, those participants that completely clear hypnozoite

batches increase the total person-time at risk in the treatment arm, leading to a competing

positive bias that was present in all trial simulations. This bias was eliminated if efficacy was

calculated based upon the proportion at risk using the complete record of recurrent infections

(Fig. S1).

In addition to the effect of transmission intensity itself, the effect of heterogeneous biting

on efficacy estimates was modulated by the transmission intensity of the trial location. At a low

EIR of 0.1, efficacy estimates were insensitive to changes in the level of heterogeneity in biting

(Fig. 2A), because the upper bound of trial participants reinfected during follow-up was 0.73%

(SD: 0.18%). By contrast, at intermediate EIRs of 1 and 10, the downward bias was reduced with

greater heterogeneity in biting. Efficacy measured at an EIR of 10 ranged from 0.58 (0.52 - 0.62)

under homogeneous biting to 0.74 (0.72 - 0.76) under the highest level of heterogeneity in biting

simulated. Heterogeneous biting reduced the downward bias caused by frequent reinfection,

because fewer infections observed during follow-up were reinfections from mosquito biting. For

example, at an EIR of 10, the proportion of individuals re-infected during follow-up ranged from

74% (SD: 0.94%) under homogeneous biting to 18% (0.78%) at the highest level of

heterogeneity in biting simulated.

At an EIR of 100, efficacy estimates had a non-monotonic relationship with the extent of

heterogeneous biting (Fig. 2A). At high transmission intensities, greater heterogeneity in biting

contributed to greater variation in anti-parasite immunity among trial participants. Trial

participants that were more frequently exposed to mosquito biting were expected to have greater

levels of anti-parasite immunity, thereby reducing the detectability of each *P. vivax* infection

during follow-up. Therefore, although the percentage of participants reinfected during follow-up

decreased monotonically with greater heterogeneity in mosquito biting, the percentage of

participants with a detectable reinfection (e.g., clinical or subclinical/LM-detectable) varied non-

monotonically and was 36% (1.0%), 38% (1.0%), 34% (1.0%), and 23% (1.0%) when the

respective variance in exposure to biting was 0, 1, 2, and 3 (Fig. 2B-E).

Figure 2. Effect of transmission intensity and heterogeneity in biting on efficacy estimates. *(A)*
LM-detectable recurrence free efficacy estimated from simulated clinical trials is shown at
different entomological inoculation rates (EIR) and levels of heterogeneity in biting. Each point
represents the median of 200 simulations, and each bar is the interquartile range. The color
represents the degree of heterogeneity in individual-level exposure to biting, corresponding to
the distributions in (B-E). Darker colors indicate greater heterogeneity in individual-level
exposure to biting, and the dotted line is the clearance probability. The distributions of biting
propensities are shown from representative simulated trials where the variance in the logged
biting propensity was equal to (B) zero, (C) one, (D) two, or (E) three.

Effect of the Rate of Relapse and Duration of Follow-up

We next examined how the rate of relapse of *P. vivax* hypnozoites and the duration of follow-up

of trial participants interact to affect efficacy estimates. We varied the mean time to relapse from

30 to 180 days and simulated phase-III clinical trials in which participants were followed for 90,

180, 365, or 730 days. To assess the effect of transmission intensity, all trials were simulated at

EIRs of 0.1, 1, 10, and 100, assuming homogeneous biting.

For a given duration of follow-up, efficacy estimates decreased with a longer mean time

to first relapse (Fig. 3A). In simulated trials in which participants were followed for 180 days at

an EIR of 1, we estimated that the efficacy of an 8-aminoquinoline with a clearance probability

of 0.75 decreased from 0.70 (IQR: 0.68 - 0.72) to 0.59 (0.56 - 0.62) as the mean time to first

relapse increased from 30 to 180 days. This bias toward the null occurred because, as the mean

time to first relapse increased, fewer trial participants were expected to relapse within the

duration of follow-up (Fig. 3B), causing the distribution of times to first recurrent infection to

appear more similar across trial arms. Only 63.2% of participants were expected to relapse by

180 days when the mean time to first relapse was 180 days, compared to 99.8% of participants

when the time to first relapse was 30 days.

For a given mean time to first relapse, our efficacy estimates decreased with a longer

duration of follow-up (Fig. 3A). With an EIR equal to 1 and a mean time to first relapse of 30

days, we estimated that the efficacy of an 8-aminoquinoline was 0.73 (0.70 - 0.75) when trial

participants were followed for 90 days, compared to 0.54 (0.52 - 0.56) when trial participants

were followed for 730 days. Under an alternative scenario in which the EIR was 10, the

estimated efficacies were 0.70 (0.65 - 0.74) and 0.39 (0.37 - 0.43) at the respective durations of

follow-up. The downward bias occurred because a longer duration of follow-up ensured that

more trial participants were reinfected by mosquito biting (Fig. 3C), similarly causing the

distribution of times to first recurrent infection to appear more similar across the trial arms. By

90 days of follow-up, 12% and 71% of trial participants were expected to have been reinfected

when the respective EIRs were 1 and 10. By 730 days of follow-up, 63% and 100% of trial

participants were now expected to have been reinfected at respective EIRs of 1 and 10.

Figure 3. Effect of rate of relapse and duration of follow-up on efficacy estimates. *(A) LM-detectable recurrence-free efficacy estimated from simulated clinical trials is shown at different entomological inoculation rates (EIRs), mean times to relapse, and durations of follow-up. Each point is the median of 200 simulations, and each bar is the interquartile range. The color represents the mean time to relapse, and each vertical strip for each EIR is the duration of follow-up (90, 180, 365, or 730 days). The dotted line is the clearance probability simulated in each trial. (B) The percentage of trial participants expected to relapse as a function of the duration of follow-up is shown for different mean times to relapse. (C) The percentage of trial participants expected to be reinfected as a function of the duration of follow-up is shown for different EIRs.*

Effect of Vector Control

Higher transmission intensity biased our efficacy estimates downward, because trial participants

in both the treatment and control arms were frequently reinfected (Fig. 2A). We assessed the

potential of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) to protect

trial participants from reinfection and therefore reduce the downward bias due to transmission

intensity. Because the effects of LLINs and IRS depend upon vector bionomics, we varied the

proportion of bites that occurred indoors and the proportion of bites that occurred while trial

participants were in bed.

208   Vector control interventions were effective in reducing the downward bias due to

transmission intensity in trial locations where the vector was predominantly endophagic (i.e.,

feeds indoors) (Fig. 4). With an endophagic vector with no preference in biting time and at an

EIR of 10, the estimated efficacies improved from 0.52 (0.46 - 0.57) in the absence of vector

control to 0.57 (0.53 - 0.62) with LLINs, 0.61 (0.56 - 0.66) with IRS, and 0.65 (0.60 - 0.69) with

the combination of LLINs and IRS (Fig. 4A). By comparison, with an exophagic vector with no

preference in biting time and at an EIR of 10, efficacy estimates improved only slightly from

0.52 (0.48 - 0.57) in the absence of vector control and 0.52 (0.47 - 0.57) with LLINs to 0.53

(0.49 - 0.58) with IRS and 0.53 (0.48 - 0.58) with the combination of LLINs and IRS (Fig. S2D).

217   Across all mosquito biting behaviors simulated, the combination of LLINs and IRS was

218   generally more effective than either intervention in isolation in reducing the downward bias in

219   efficacy estimates (Fig. S2). When considering interventions in isolation, IRS was more effective

220   than LLINs in reducing the downward bias, and the distribution of LLINs most improved

221   efficacy estimates under scenarios in which an appreciable number of mosquito bites were taken

222   at night while trial participants were in bed.

Figure 4. Effect of vector control on efficacy estimates. *The impact of LLIN distribution (red),
IRS administration (green), and combined LLIN distribution and IRS administration (teal) on
resolving biases in LM-detectable recurrence free efficacy estimates is compared to a no-
intervention scenario (dark blue) across a range of entomological inoculation rates (EIR). Each
point represents the median of 200 simulations, and each bar is the interquartile range. The
dotted line is the clearance probability simulated in each trial. The absolute proportion of bites
occurring indoors (Φ_I) was 0.90 and in bed (Φ_B) was 0.45.*

Effect of Parasite Genotyping

Unlike vector control interventions that reduce the downward bias in efficacy by reducing the

number of reinfection events among trial participants (Fig. S3), parasite genotyping could correct

or reduce the downward bias by distinguishing recurrent infection events that directly reflect the

clearance probability (i.e., relapses arising from hypnozoite batches acquired prior to treatment)

from all other recurrent infections. We assessed the potential of a generic genotyping method to

correct the bias in efficacy estimates at different transmission intensities and considered how

performance characteristics of the genotyping method affected the extent to which the bias was

corrected by varying the sensitivity and specificity of the genotyping method. For the purpose of

this simulation study, we defined sensitivity as the probability of correctly identifying relapses

caused by hypnozoite batches acquired prior to treatment and specificity as the probability of

correctly identifying all other recurrent infections (e.g., reinfections and relapses caused by

hypnozoite batches acquired after treatment).

At lower and intermediate transmission intensities (i.e., EIRs of 0.1 and 1), efficacy

estimates changed more with improved sensitivity than improved specificity of the genotyping

method. By contrast, at higher transmission intensities, a genotyping method with high

specificity was needed to reduce the downward bias in efficacy. At an EIR of 100 and assuming

100% sensitivity of the genotyping method, the estimated efficacy of an 8-aminoquinoline with

clearance probability equal to 0.75 improved from 0.38 (0.33 - 0.44) at 25% specificity to 0.67

(0.62 - 0.71) at 100% specificity. Under the alternative scenario in which specificity of the

genotyping method was 100%, the estimated efficacy at the respective EIR improved from 0.48

(0.35 - 0.58) at 25% sensitivity to 0.67 (0.62 - 0.71) at 100% sensitivity. The specificity of the

genotyping method was more important at higher EIR, because, at an EIR of 100, 100% of

participants were expected to be reinfected during follow-up (Fig. 3C). Misclassifying

reinfection events as failures of 8-aminoquinoline treatment (i.e., relapses caused by hypnozoites

batches acquired prior to treatment) lead to a greater downward bias, so a highly specific method

was needed in settings where trial participants were frequently reinfected. These effects were less

pronounced at low transmission intensities, given that fewer trials participants were reinfected

during follow-up.

Figure 5. Effect of parasite genotyping on efficacy estimates. *The impact of genotyping recurrent infections to estimate the efficacy of radical cure is shown for different sensitivities and specificities of the genotyping method across a range of entomological inoculation rates (EIR). Sensitivity of the genotyping method is the probability of correctly identifying a relapse caused by hypnozoites acquired prior to treatment, and specificity of the genotyping method is the probability of correctly identifying all other recurrent infections. For a given EIR, the vertical panels correspond to the specificity of the genotyping method, and the colors of the points within a given panel denote the sensitivity of the genotyping method. Each point represents the median of 200 simulations, and each bar is the interquartile range. The dotted line is the clearance probability simulated in each trial.*

Effect of the 8-aminoquinoline

The previous analyses considered phase-III trials of an 8-aminoquinoline that provided

prophylaxis for 28 days, a duration of time less than the 32-day period of left-censoring used to

calculate efficacy. Consequently, prophylaxis did not impact our efficacy estimates. To examine

whether a longer duration of prophylaxis biased our efficacy estimates, we simulated phase-III

trials for two different 8-aminoquinolines, PQ and TFQ, that provide prophylactic effects for

fixed periods of 28 and 45 days, respectively. Because the benefit of prophylaxis increases with

transmission intensity, we simulated trials at EIRs equal to 0.1, 1, 10, and 100, assuming

homogeneous biting.

A longer duration of prophylaxis biased our efficacy estimates upward, though the

magnitude of the bias depended upon transmission intensity (Fig. 6). In a low-transmission

setting (i.e., EIR of 0.1), our efficacy estimates did not change with an increased duration of

prophylaxis, because, on average, only 0.058% (SD: 0.081%) of participants in the control arm

were reinfected between days 32 and 45 post-enrollment—the time period over which TFQ

provided prophylactic effects not accounted for by left-censoring. Consequently, at an EIR of

0.1, we estimated that the efficacies of TFQ and PQ were both 0.80 (0.79 - 0.81). At higher

EIRs, we estimated a greater efficacy for TFQ than PQ, because participants in the control arm

were frequently reinfected whereas participants in the treatment arm were protected from

reinfection. On average, the percentage of participants in the control arm who were reinfected

between 32- and 45-days post-enrollment was 1.5% (SD: 0.38%), 9.4% (SD: 1.0%), and 52%

(2.2%) at EIRs of 1, 10 and 100, respectively. Consequently, we estimated that the respective

efficacies of TFQ and PQ were 0.69 (0.66 - 0.72) and 0.67 (0.65 - 0.70) at an EIR of 1, 0.60

(0.55 - 0.64) and 0.56 (0.52 - 0.61) at an EIR of 10, and 0.42 (0.38 - 0.47) and 0.35 (0.30 - 0.40)

at an EIR of 100.

Figure 6. Effect of 8-aminoquinoline on efficacy estimates. LM-detectable recurrence free efficacy estimated from simulated clinical trials is shown for primaquine (purple) and tafenoquine (blue) at different entomological inoculation rates (EIR). Each point is the median of 200 simulations, and each bar is the interquartile range. The dotted line is the clearance probability simulated in each trial.

Effect of the efficacy metric and infection endpoint

To test whether the efficacy estimates that we obtained were sensitive to the choice of efficacy

metric and the infection endpoint, we simulated phase-III clinical trials in which trial participants

were assessed for PCR-detectable, LM-detectable, or clinical infections during follow-up. Trials

were simulated at EIRs of 0.1, 1, 10, and 100 assuming homogeneous biting, and efficacy was

calculated using three metrics: (1) Cox proportional hazards model, (2) incidence rates, and (3)

the proportion at risk.

For all three efficacy metrics considered, increasing transmission intensity caused a

downward bias in efficacy estimates, because, at higher transmission intensities, most

participants in both the treatment and control arms experienced a reinfection or relapse during

follow-up (Fig. 7). For PCR-detectable infections, estimated efficacy was highest if calculated

using the Cox proportional hazards model and lowest if calculated using the proportion at risk.

This suggested that, in the absence of parasite genotyping (Fig. S1), the magnitude of bias caused

by reinfection from mosquito biting was more severe when basing efficacy upon incidence rates

or the proportion at risk than upon proportional hazards.

The sensitivity of the assay by which trial participants were assessed for recurrent

infections also affected our efficacy estimates, though the direction of the effect depended upon

the chosen efficacy metric. For efficacy estimates based upon incidence rates or the proportion at

risk, shifting from a more sensitive assay (i.e., PCR-based detection) to a less sensitive assay

(i.e., monitoring for clinical infections) reduced the downward bias due to reinfection,

particularly at higher transmission intensities. This was due to the fact that the fraction of

recurrent infections ascertained increased with a more sensitive assay, causing us to detect more

recurrent infections during follow-up and making the incidence rates and proportions at risk

appear more similar across the treatment and control arms. By contrast, for efficacy estimates

based upon the Cox proportional hazards model, efficacy estimates were lower for a less

sensitive assay at EIRs of 0.1, 1, and 10. A less sensitive assay resulted in the time to the first

detected recurrent infection occurring later during follow-up for participants in both the

treatment and control arm, causing the observed downward bias. At a very high transmission

intensity (i.e., EIR of 100), a less sensitive assay minimized bias, because effectively all trial

participants were expected to be reinfected during follow-up (Fig. 2C).

335

Figure 7. Effect of efficacy metric and infection endpoint on efficacy estimates. *Efficacy
estimates obtained from simulated clinical trials is shown when calculated using the Cox
proportional hazards model, incidence rates, or the proportion at risk. Efficacy calculations
were performed using clinical (maroon), LM-detectable (red), and PCR-detectable (orange)
recurrent infections identified during follow-up as the infection endpoint. Each point is the
median of 200 simulations, and each bar is the interquartile range. The dotted line is the
clearance probability simulated in each trial.*

DISCUSSION

Obtaining standardized estimates of the effect of radical cure on *P. vivax* hypnozoites is

challenging, because the recurrent infection endpoint used in phase-III clinical trials includes

infection events, such as reinfections by mosquito biting, that do not reflect the effect of radical

cure on *P. vivax* hypnozoites. In this simulation study, we identified features of the trial setting,

including transmission intensity, heterogeneous feeding patterns, and the relapse rate of the *P.*

vivax parasite, that affected our estimates of efficacy and the utility of clinical trial data to assess

the extent to which radical cure prevents relapse. We demonstrated that the use of vector control

and genotyping methods are two approaches that can reduce and, in some cases, even correct

these site-specific biases and yield more standardized estimates of efficacy against relapse.

In the recent GATHER, DETECTIVE, and IMPROV trials (6–9), efficacy estimates

varied across trial sites. Interpreting site-specific differences in efficacy is important for past and

future clinical trials (19), and our simulation results suggest that the differences in efficacy

estimates could be caused by site-specific biases that arise when the infection endpoint used to

measure efficacy does not directly reflect the action of the therapeutic being trialed. If the trial

sites vary in transmission intensity, our results suggest that efficacy estimates could be lower in

high-transmission settings, because trial participants are more frequently reinfected during

follow-up. Greater heterogeneity in mosquito biting reduces this downward bias by reducing the

number of trial participants who are bitten and possibly reinfected during follow-up, though this

effect is non-monotonic at very high transmission intensities due to the predicted interaction with

anti-parasite immunity. Trial sites may also differ in the rates at which *P. vivax* hypnozoites

relapse (17). A longer time to relapse implies that an appreciable number of trial participants will

not yet have relapsed during follow-up, thereby biasing efficacy estimates downward (20).

Increasing the duration of follow-up further compounds the bias rather than corrects it, because a

long duration of follow-up causes more participants in both the treatment and control arms to

become reinfected by mosquito biting, particularly at higher transmission intensities. Finally,

frequent reinfection at higher transmission intensities makes the comparison of treatment

regimens with different durations of prophylaxis challenging, because a longer duration of

prophylaxis prevents more individuals in the treatment arm from reinfection. This results in an

upward bias that may cause us to overestimate the effect against hypnozoites of treatment

regimens that provide a longer period of prophylaxis, such as tafenoquine co-administered with

chloroquine.

In general, there was greater bias in high-transmission settings, because of the higher risk

of recurrent infections being due to reinfections from new mosquito bites. In low-transmission

settings, this bias is reduced, although there is the concomitant challenge of recruiting sufficient

trial participants. Our simulation results suggest that trial investigators can reduce bias by

prospectively preventing reinfections with vector control or by retrospectively accounting for

reinfections by parasite genotyping. LLINs and IRS were predicted to be most effective in trial

settings with an endophagic vector that takes most bites indoors, so novel vector control

interventions, such as spatial repellents, may be needed in settings with an exophagic vector to

reduce peri-domestic biting (21). Entomological data collected prior to trial enrollment could

characterize the local vector bionomics and inform the selection of interventions (22,23), and

blood meal analysis (24–26) or serological assays (27,28) performed as part of the trial could

quantify heterogeneous feeding, a factor that directly affects the magnitude of the site-specific

bias.

Our results demonstrate that parasite genotyping could be used to generate less biased

efficacy estimates that better reflect the effect of the 8-aminoquinoline against hypnozoite

batches. Although in practice the sensitivity of a genotyping method may be reduced by not

observing infections that occurred prior to trial enrollment, the extent to which genotyping

reduced bias in our analysis was robust to changes in sensitivity and depended most upon the

specificity. High specificity can likely be achieved given the high expected heterozygosity of

microsatellite and amplicon deep sequencing panels, as well as the ability to detect minority

clones in multiclonal *P. vivax* infections (29–33). Statistical frameworks leveraging genotyping

data to distinguish relapses from reinfections have been successfully developed and could be

readily integrated into the analysis of future clinical trial data (12,33).

Beyond the factors that make resolving differences in efficacy challenging within the

context of a single trial, we identified features of trial design that could limit the comparability of

efficacy estimates across trials. Specifically, the details of how the efficacy endpoint was

calculated (e.g., time to first infection vs. incidence ratio) and the sensitivity of the assay used to

detect recurrent infections resulted in considerable variation in efficacy estimates, particularly at

higher transmission intensities. These results suggest that future studies performing meta-

analyses of the efficacy of radical cure should consider differences in the trial designs of the

clinical trials included.

There are a number of limitations of this analysis. First, we did not calibrate our model to

clinical trial data, so our results are not representative of any specific trial settings. However, our

simulations encompassed a wide range of epidemiological settings, so the site-specific biases

identified in our analysis should reflect variation possible across trial sites. Second, there remains

much about hypnozoite biology that is not well understood (34), so our simplified representation

of hypnozoite activation and death in our transmission model may not fully capture reality.

Finally, we have an imperfect understanding of the acquisition and loss of anti-parasite and

clinical immunity (35). Underestimating the level of anti-parasite and clinical immunity among

trial participants may lead to a greater fraction of recurrent infections detected during follow-up

than would occur in an actual trial context. This could have led us to overestimate site-specific

biases, in which case more refined mathematical representations of immunity could be beneficial

for future studies building on ours (10,36).

Our analysis predicted that site-specific biases are likely to occur in phase-III trials for

radical cure, and these results suggest that care should be taken in the planning of future trials

and the interpretation of trial data. Mathematical modeling that accounts for site-specific biases

can aid in the interpretation of clinical trial data and may be useful for informing the choice of

efficacy metric and identifying future trial sites where biases may be less severe (37). As always,

the utility of the insights from mathematical models is improved with additional data, so

modeling should be integrated into clinical trial design to identify data needs and inform data

collection in order to reduce these biases and improve understanding of radical cure's potential to

control *P. vivax* malaria.

METHODS

Transmission Model

To simulate *Plasmodium vivax* transmission, we used a stochastic, individual-based model

developed by White *et al.* (10) and Nekkab *et al.* (18). This model extends the Ross-MacDonald

framework of *P. falciparum* transmission to incorporate relapses (38), a characteristic feature of

P. vivax transmission (39). Calibrated to epidemiological surveys conducted in Papua New

Guinea, the Solomon Islands, and Brazil, the model by White *et al.* (10) and Nekkab *et al.* (18)

reproduces *P. vivax* transmission dynamics across a range of epidemiological settings.

The rates at which individuals in the population are reinfected and relapse depend upon

the respective number of infectious mosquito bites received (i.e., the entomological inoculation

rate, or EIR) and the number of hypnozoite batches present in each individual's liver. The

average EIR within the population is determined by the mosquito population dynamics, and

individual variation therein is due to heterogeneity in exposure and age-dependent differences in

biting. Following successful inoculation with *P. vivax* sporozoites from an infectious mosquito

bite, an individual experiences a primary bloodstream infection and accumulates an additional

batch of hypnozoites within the liver. In the absence of treatment, each batch of hypnozoites can

activate to cause relapses or be cleared naturally from the liver according to fixed rates (Table

S1).

The nature of each blood-stage infection (e.g., reinfection or relapse) is determined by the

level of anti-parasite and clinical immunity in the infected individual. In the model, the level of

anti-parasite immunity determines the probability that a blood-stage infection is detectable by

light microscopy (LM) and also increases the rate at which low-density infections are cleared.

The level of clinical immunity determines the probability that an individual with a blood-stage

infection exhibits symptoms.

The levels of anti-parasite and clinical immunity interact to determine the detectability of

each blood-stage *P. vivax* infection. The model by White *et al.* (10) and Nekkab *et al.* (18)

considers three types of blood-stage infections: (1) sub-microscopic infections detectable by

PCR; (2) subclinical infections detectable by LM and PCR; and (3) clinical infections detectable

by LM and PCR. Following White *et al.* (10) and Nekkab *et al*. (18), we assumed that each

clinical infection was characterized by a fever exceeding 38°C within the last 48 hours and a

parasite density greater than 500/µL. Individuals with clinical *P. vivax* infections then seek

treatment with anti-malarial drugs according to a probability of treatment-seeking behavior.

Simulation of the *P. vivax* transmission model occurs in two steps. First, the population is

initialized at equilibrium according to the analogous set of deterministic compartmental

differential equations. Then, the stochastic, individual-based model is simulated with the

initialized population. For further description of the model and its assumptions, please refer to

Tables S1-S3 and the documentation provided in White *et al.* (10) and Nekkab *et al.* (18).

Trial Overview

We constructed phase-III clinical trials for a generic 8-aminoquinoline (e.g., primaquine or

tafenoquine). We simulated trials in order to quantify the recurrence-free efficacy as a measure

of the therapeutic effect of radical cure against the hypnozoite batches present in each individual

presenting with a clinical *P. vivax* infection confirmed by light microscopy.

We designed our simulated phase-III clinical trials to be comparable to previous trials of

PQ and TFQ (6–8). Participants were randomly assigned to the treatment and control arms, and

all participants received chloroquine (CQ) upon enrollment to clear the *P. vivax* blood-stage

infection. Consistent with the DETECTIVE trial (6,8), participants were followed for 180 days

and assessed for asexual parasitemia by light microscopy at days 8, 15, 22, 29, 60, 90, 120, and

180 post-enrollment. For trials simulated with longer duration of follow-up, additional time

points were included. See supplement for further details.

Radical Cure Model

We modeled the action of radical cure in each individual receiving treatment as the per-

hypnozoite batch probability of clearance. To allow for heterogeneous action of the intervention

(40), we assumed that a proportion p_i of the population belonged to each stratum *i* with per-

hypnozoite batch clearance probability, c_i. For a population consisting of two strata, the mean

per-hypnozoite batch probability of clearance was

487
$$\bar{c} = p_1 c_1 + p_2 c_2, \quad (1)$$

where $p_2 = 1 - p_1$. This model of heterogeneous action of radical cure generalized the

intervention actions commonly considered in the evaluation of clinical trials. Under the "leaky"

model (40–42), the action of radical cure is the same across all individuals in the population

($p_1 = 1$) with $0 \leq c_1 \leq 1$. Under the "all-or-none" model (40–42), radical cure completely

clears hypnozoites in a subset of the population ($0 < p_1 < 1; c_1 = 1$) and has no effect on the

hypnozoites in the remainder of the population ($p_2 = 1 - p_1; c_2 = 0$). These two models of

intervention action could manifest due to host-specific factors, most notably the inherited blood

disorder glucose-6-phosphate dehydrogenase deficiency (G6PDd) and cytochrome P-450

isoenzyme 2D6 (CYP2D6) genotype, an enzyme involved in metabolizing PQ. Rather than

directly affect PQ or TFQ efficacy, G6PDd requires individuals to be excluded from clinical

trials due to the risk of hemolysis. For individuals with a low CYP2D6 metabolization

phenotype, it has been shown that PQ does not prevent *P. vivax* relapses (11). Despite advances

in the understanding of CYP2D6 metabolization (43), its association with 8-aminoquinoline

efficacy remains poorly understood. For example, under an "all-or-none" action, CYP2D6

metabolization could manifest as a binary phenotype with high metabolizers effectively clearing

hypnozoite batches and low metabolizers failure to clear hypnozoite batches. Alternatively,

under a "leaky" action, all treated individuals partially clear hypnozoite batches. Supplementary

analyses revealed that the choice of intervention action did not substantially affect our efficacy

estimates generated using the Cox proportional hazards model (Fig. S4). Therefore, we assumed

by default that each 8-aminoquinoline had an "all-or-none" action.

Under the model of heterogeneous action of radical cure, the number of batches of

hypnozoites following treatment was distributed as

512                    $$H_{post} \sim Binomial(H_{pre}, 1 - c_i), \forall i \in \{1,2\}. \quad (2)$$

In eq. (2), H_{pre} is the number of batches of hypnozoite present in the liver prior to treatment, and

c_i is the per-hypnozoite batch clearance probability for an individual in stratum i.

Trial Design

We constructed our simulated phase-III clinical trials for radical cure to match the trial design

used in past trials for PQ and TFQ (6–8). Accordingly, we considered four phases of the

randomized control trial design: (1) recruitment, (2) treatment, (3) vector control, and (3) follow-

up.

Recruitment

We enrolled individuals in the simulated clinical trial if they presented at a health clinic with

febrile illness and were diagnosed by light microscopy with a *P. vivax* infection. Consistent with

the DETECTIVE trial (6,8), participants were enrolled if they were at least 16 years of age and

had a measured glucose-6-phosphate dehydrogenase (G6DP) activity greater than 70% of the

median value of the trial location. Following Nekkab *et al*. (18), we assumed that G6PD activity

was measured using the SD Biosensor STANDARD G6PD test (44). This test qualitatively

classifies G6PD activity as normal (>70% activity), intermediate (30-70% activity), and low

(<30% activity).

Individuals that met the criteria for enrollment were then randomly assigned to the

treatment or control arm of the clinical trial. Allocation of participants to each trial arm occurred

with equal probability, provided that the current number of participants in each arm was less than

the desired sample size of 1,000.

Treatment

Upon enrollment, all trial participants were treated with a 3-day course of CQ to clear the blood-

stage, asexual parasites (6,8). We assumed that treatment with CQ was 100% effective and that

there were no recrudescences among trial participants. Participants in the treatment arm were

also treated with an 8-aminoquinoline to clear the hypnozoite reservoir. For individuals in the

treatment arm, the number of hypnozoite batches following radical cure was calculated

according to eq. (2). We further assumed that treatment with the 8-aminoquinoline provided both

blood-stage and liver-stage prophylaxis. Consistent with White *et al.* (10) and Nekkab *et al*. (18),

we assumed that the duration of prophylaxis was 28 days for PQ when co-administered with CQ

and 45 days for TFQ when co-administered with CQ.

Vector Control

As in the DETECTIVE trial (6,8), all participants were provided with a long-lasting insecticidal

net (LLIN) to prevent reinfection from mosquitoes during follow-up and therefore decrease the

potential bias that may arise in calculating efficacy based on a recurrent infection endpoint.

Following Griffin *et al*. (36) and White *et al*. (10), we assumed that vector control measures

decrease the probabilities of mosquito biting and successful feeding and increase the

probabilities of repellency and death. The magnitude of the effect depends upon the proportion

of mosquito bites that occur while individuals are indoors (Φ_I) and in bed (Φ_B), the duration of

usage of the LLIN, and the duration of insecticidal activity. We assumed that the mean duration

of usage of LLINs was 3 years and that the mean duration of insecticidal activity was 2.5 years.

We also considered whether the use of indoor residual spraying (IRS) in each

participant's house administered in isolation or in combination with LLINs decreased the

potential bias in our efficacy estimates. As with LLINs, we assumed that the use of IRS

decreases the probabilities of mosquito biting and successful feeding and increases the

probabilities of repellency and death (10,36). To account for the waning effect of IRS over time,

we assumed that the mean duration of insecticidal activity was 6 months.

Follow-up

We followed each participant for 180 days following enrollment in the clinical trial and

treatment with anti-malarial drugs. Consistent with the DETECTIVE trial (6,8), for each

participant, we recorded the date of each clinical *P. vivax* infection that occurred within the

duration of follow-up. Furthermore, we tested each participant for *P. vivax* asexual parasites

using light microscopy on days 8, 15, 22, 29, 60, 90, 120, 160, and 180 post-enrollment.

To examine potential biases that arise from trial surveillance methods, we kept a

complete record of all recurrent infections that occurred within the duration of follow-up,

including those that would not have been detected under the trial protocol. For each recurrent

infection, we recorded the cause (i.e., reinfection or relapse) and the type of blood-stage infection

(e.g., sub-microscopic, sub-clinical, or clinical). We further distinguished between relapses

caused by hypnozoite batches acquired prior to treatment and relapses caused by hypnozoites

batches acquired following treatment. Only relapses caused by hypnozoite batches acquired prior

to treatment reflect the action of 8-aminoquinoline treatment against hypnozoites batches.

Statistical Analyses

We calculated the efficacy of the 8-aminoquinoline used in each clinical trial from the output

collected in each respective simulation. We calculated efficacy using multiple metrics in order to

examine how different data collected during trial follow-up resolved biases in the efficacy

estimates.

Consistent with previous phase-III clinical trials (6,8), we used freedom from LM-

detectable recurrent infection as the default efficacy metric in our simulation studies. We

calculated efficacy using the Cox proportional hazards model (45), which computes the hazard

ratio between the treatment and control arms based on the times to first LM-detectable recurrent

infection. Following the DETECTIVE trial protocol (6,8), recurrent infections that occurred

before 32 days post-enrollment were not included. Given that the timing of each recurrent

infection was unobserved, all trial participants were interval censored.

We calculated efficacy using incidence rates computed from the recurrent infections that

occurred within the duration of follow-up. We calculated efficacy based on incidence rates as

595
$$E_{IR} = 1 - \frac{e_t/y_t}{e_c/y_c}. \quad (3)$$

In eq. (3), e_t and e_c are the respective number of infection events in the treatment and control

arms, and y_t and y_c are the respective number of person-years of follow-up in the treatment and

control arms (42,45).

The magnitude of the measured efficacy also depends upon the action of the radical cure

therapeutic. In absence of other sources of bias, we will overestimate efficacy for 8-

aminoquinolines that elicit an "all-or-none" response if we calculate efficacy based on incidence

rates. This phenomenon is caused by the subset of individuals in the treatment arm who

completely clear the hypnozoites from their livers and increase the number of person-years of

follow-up (42). To resolve this bias that arises from the assumption of intervention action, we

calculated efficacy based on risk as

608
$$E_R = 1 - \frac{p_t}{p_c}, \quad (4)$$

where p_t and p_c are the proportion of individuals in the treatment and control arms that

experience a particular infection event within the duration of follow-up.

Simulation Experiments

We performed simulation experiments to quantify biases in the efficacy estimates that may arise

under different transmission settings and other features of the clinical trial design. First, we

considered how our efficacy estimates varied with transmission intensity and heterogeneity in

mosquito biting patterns. Second, we considered how differences in the rate of relapse of the *P.*

vivax hypnozoites interact with the duration of the trial follow-up and the transmission intensity

to bias our estimates of efficacy. After characterizing these biases, we assessed whether the

allocation of vector control measures, such as LLINs and IRS, to trial participants could prevent

reinfections and thereby reduce the bias in the efficacy estimates. We next considered whether a

genotyping method capable of distinguishing between different types of *P. vivax* recurrent

infections at different sensitivities and specificities could reduce or correct the bias in the

efficacy estimates. Then, we measured the extent to which the duration of prophylaxis provided

by the treatment regimen biases our estimates of efficacy by preventing reinfections in the

treatment arm only. Finally, we considered how the efficacy estimates that we obtained varied

with the choice of efficacy metric and infection endpoint.

For each simulation setting, we simulated a phase-III clinical trial with 1,000 participants

in each arm. This sample size was chosen to ensure that the power of our clinical trials exceeded

95% for each transmission intensity and efficacy metric considered (Fig. S5). Each trial was

simulated in a population of 200,000 individuals, and the maximum duration of each trial was 15

years in order to ensure that complete enrollment was attained, even at low transmission

intensities. By default, PQ was the 8-aminoquinoline provided to the participants in the treatment

arm and when co-administered with CQ provided 28 days of blood-stage and liver-stage

prophylaxis during which trial participants could not become reinfected or relapse. The mean

per-hypnozoite batch probability of clearance was equal to 0.75. For each simulation setting, we

simulated trials in which the therapeutic had an "all-or-none" response. Because the transmission

model was stochastic, we ran 200 simulations for each simulation setting and computed the mean

and interquartile range for the efficacy estimates across these simulations. By default, we defined

efficacy as freedom from LM-detectable recurrent infection calculated using the Cox

proportional hazards model.

Table 1. Parameters Varied during the Simulation Analyses. The parameters that were varied during each simulation analysis are reported. All other parameters in the transmission model are set to default values and are consistent with the values reported in Tables S1 and S2.

Variance in Mosquito Biting	Time to Relapse (d)	Follow-up (d)	Prophylaxis (d)
Effect of Transmission Intensity and Heterogeneity in Biting			
0, 1, 2, 3	65	180	28
Effect of Rate of Relapse and Duration of Follow-up			
0	30, 60, 90, 180	90, 180, 365, 730	28
Effect of Vector Control / Genotyping / Efficacy Metric and Infection Endpoint			
0	65	180	28
Effect of the 8-aminoquinoline			
0	65	180	28,45

Availability of Code

All code to reproduce the analyses in this study is available on Github at

https://github.com/johnhhuber/Radical_Cure_Uncertainty.

ACKNOWLEDGMENTS

JHH acknowledges funding from a National Science Foundation Graduate Research Fellowship

and a Richard and Peggy Notebaert Premier Fellowship from the University of Notre Dame. CK

received funding from NIH R21-AI137891. NN and MTW were supported by a grant from

Medicine for Malaria Venture. NN also received funding from a Pasteur Roux-Cantarini

Fellowship. This publication was made possible with partial support from Grant Numbers TL1

TR002531 and UL1TR002529 (A. Shekhar, PI) from the National Institutes of Health, National

Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The

funders had no role in study design, data collection and analysis, decision to publish, or

preparation of the manuscript.

COMPETING INTERESTS

The authors have no competing interests to declare.

SUPPORTING INFORMATION

Methods

Transmission Model

Table S1. Default Transmission Setting Parameters for the Human Component of the
Transmission Model. *A description of the default parameters used in the individual-based model*
to simulate clinical trial data are provided along with the numeric values and the corresponding
references.

Parameter	Value	Reference
Demographics		
Mean Age of Population	31.8 years	Assumed
Max Age of Population	80 years	Assumed
Proportion of Pregnant Women	7.5%	Assumed
G6PD Deficiency Prevalence	0%	Assumed
CYP-2D6 Phenotype Prevalence	0%	Assumed
Exposure to Mosquito Biting		
Degree of Age-Dependent Biting	0.85	(46,47)
Reference Age of Biting	8 years	(46,47)
Mosquito-to-Human Transmission Probability	0.50	(18)
Hypnozoite Dynamics		
Rate of Relapse	$1/65 \text{ day}^{-1}$	(18)
Rate of Liver-Stage Hypnozoite Clearance	$1/383 \text{ day}^{-1}$	(10)

672 *Table S2. Default Infection Dynamics Parameters for the Human Component of the*
673 *Transmission Model. A description of the default parameters used in the individual-based model*
674 *to simulate clinical trial data are provided along with the numeric values and the corresponding*
675 *references.*

Parameter	Value	Reference
Human Infection Duration		
Latent Period	10 days	(48)
Max PCR-Detectable Infection (No Immunity)	70 days	(10)
Min PCR-Detectable Infection (Full Immunity)	10 days	(10)
LM-Detectable Infection	10 days	(18)
Clinical Disease (Untreated)	5 days	(10)
Clinical Disease (Treated)	1 day	(10)
Immunity		
Anti-Parasite Immune Boosting Refractory Period	19.77 days	(18)
Duration of Anti-Parasite Immunity	10 years	(10)
Probability of LM-Detectable Infection (No Immunity)	0.8918	(18)
Probability of LM-Detectable Infection (Full Immunity)	0.0043	(18)
Anti-Parasite Immunity for 50% Reduction in Duration of LM-Detectable Infection	27.52	(18)
Shape Parameter for LM-Detectable Infection	2.403	(18)
Anti-Parasite Immunity for 50% Reduction in Duration of PCR-Detectable Infection	9.9	(18)
Shape Parameter for Duration of PCR-Detectable Infection	4.602	(18)
Clinical Immune Boosting Refractory Period	7.85 days	(18)
Duration of Clinical Immunity	30 years	(10)
Probability of Clinical Episode (No Immunity)	0.8605	(18)
Probability of Clinical Episode (Full Immunity)	0.018	(18)
Clinical Immunity for 50% Reduction in Clinical Episode	11.538	(18)
Shape Parameter for Probability of Clinical Episode	2.25	(18)
Newborn Immunity Relative to Mother's	0.421	(18)
Duration of Maternal Immunity	35.148	(18)
Infectiousness to Mosquitoes		
During PCR-Detectable Infection	0.035	(49)
During LM-Detectable Infection	0.1	(49)
During Clinical Disease	0.8	(49)
During Treated Clinical Disease	0.4	(49)

 Table S3. Default Parameters for the Mosquito Component of the Transmission Model. A
678 *description of the default parameters used in the individual-based model to simulate clinical trial*
679 *data are provided along with the numeric values and the corresponding reference.*

Parameter	Value	Reference
Mosquito Bionomics		
Mosquito Life Expectancy	6 days	(18)
Duration of Sporogony	8.4 days	(18)
Human Blood Index	0.50	(18)
Proportion of Bites Occurring in Bed	0.45	Assumed
Proportion of Bites Occurring Indoors	0.90	Assumed
Mosquito Larval Development		
Development Time of Early Larval Instars	6.64 days	(50)
Development Time of Late Larval Instars	3.72 days	(50)
Development Time of Pupae	0.64 days	(50)
Per Capita Mortality Rate of Early Larval Instars	0.034 day^{-1}	(50)
Per Capita Mortality Rate of Late Larval Instars	0.035 day^{-1}	(50)
Per Capita Mortality Rate of Pupae	0.25 day^{-1}	(50)
Daily Number of Eggs Laid per Mosquito	21.19	(50)
Effect of Density Dependence on Late Larval Instars Relative to Early Larval Instars	13.25	(50)

Trial Design

Power Calculations

To ensure that our simulated clinical trials were appropriately powered, we performed a

retrospective power analysis. We took the outputs of our simulated clinical trials performed in

transmission settings with homogeneous biting and computed the median and interquartile range

of sample sizes in each arm necessary to achieve a specific level of power at a given EIR. The

incidence rate and the proportion at risk in the control arm were computed using the full record

of LM-detectable/subclinical and clinical relapses caused by hypnozoites acquired prior to

treatment. For each power calculation, we assumed a type-I error rate of 0.05 and an efficacy of

75%.

     Using the Cox proportional hazards model (51), we first calculated the total number of

events N needed to have power β and type-I error rate α as

$$N = \frac{\left(z_\beta + z_{1-\frac{\alpha}{2}}\right)^2}{P_t P_c \log^2(E_{Cox})}, \quad (S1)$$

where z_β and $z_{1-\frac{\alpha}{2}}$ are the z-scores, P_t and P_c are the respective proportion of participants in the

treatment and control arms, and E_{Cox} is the expected efficacy. We then calculated the number of

participants in the control arm by dividing the total number of events needed by the expected

total incidence rate computed from the trial output. The number of participants in the treatment

arm was equal to the number of participants in the control arm.

Based on incidence rates, we followed Smith *et al.* (52) and computed the number of

participants in each arm as

$$n = \left(z_\beta + z_{1-\frac{\alpha}{2}}\right)^2 \frac{r_c + r_t}{(r_c - r_t)^2}, \quad (S2)$$

706   where z_β and $z_{1-\frac{\alpha}{2}}$ are the z-scores, r_c is the expected incidence rate in the control arm, and r_t is

707   the expected incidence rate in the treatment arm.

708   Based on proportion at risk, we computed the number of participants in each arm as

$$n = \left(z_\beta + z_{1-\frac{\alpha}{2}}\right)^2 \frac{2p(1-p)}{(p_c - p_t)^2}. \quad (S3)$$

In eq. (S3), z_β and $z_{1-\frac{\alpha}{2}}$ are the z-scores, p_t and p_c are the expected proportion of participants at

risk in the treatment and control arms, and p is the average of p_t and p_c (52).

Simulation Scenarios

Effect of Transmission Intensity and Heterogeneity in Biting

The transmission intensity at the trial location may determine the frequency, cause, and

detectability of recurrent infections that occur within the duration of follow-up. The number of

reinfection events experienced by each trial participant increases with EIR. Thus, at higher EIR,

the proportion of recurrent infections that are relapses caused by hypnozoites acquired prior to

treatment may be small. Moreover, the levels of anti-parasite and clinical immunity in each trial

participant is a function of exposure and transmission intensity, and, as EIR increases, fewer

recurrent infections may be detected by light microscopy. Therefore, the transmission intensity at

the trial location may bias efficacy estimates, likely downward, due to the rate at which trial

participants are reinfected by mosquitoes.

Heterogeneity in mosquito biting contributes to observed heterogeneous patterns of

Plasmodium transmission (16). For *P. falciparum*, heterogeneity in biting biases efficacy

estimates towards the null, because fewer participants in the treatment and control arms are

exposed within the duration of follow-up (42). For *P. vivax*, however, heterogeneity in biting

may reduce the bias due to transmission intensity, because fewer participants are reinfected by

mosquitoes within the duration of follow-up.

We varied the transmission intensity and the degree of heterogeneity in mosquito biting

to quantify their effect on efficacy estimates. We varied transmission intensity by simulating a

population-level EIR of 0.1, 1, 10, or 100 infectious bites per person-year (*ibppy*). To account for

heterogeneity in biting, we varied the variance of the distribution of logged biting propensities

from zero to three. This distribution determines the variation in exposure to mosquito biting

across individuals, and a zero variance implies homogeneous biting.

Effect of Rate of Relapse and Duration of Follow-up

The rate of *P. vivax* relapse varies geographically, with the estimated mean time to first relapse

ranging from 41-65 days for tropical phenotypes to 299 days for temperate phenotypes (17). If

the duration of follow-up is too short relative to the mean time to first relapse, then an

appreciable number of trial participants may not have relapsed by the duration of follow-up. A

longer duration of follow-up may capture a great proportion of relapses but also increases the

temporal window over which trial participants can become reinfected by mosquito biting. The

probability of reinfection during the duration of follow-up will vary with the EIR.

We examined the interaction between the rate of relapse, the duration of follow-up, and

transmission intensity and quantified its effect on the efficacy estimates in simulated clinical

trials. We fixed the mean time to relapse at 30, 60, 90, or 180 days and simulated clinical trials in

which the duration of follow-up was 90, 180, 365, or 730 days. Trial participants were assessed

for asexual parasites using light microscopy according to the following schedule: days 8, 15, 22,

29, 60, and 90 for the 90-day follow-up period; days 8, 15, 22, 29, 60, 90, 120, and 180 for the

180-day follow-up period; days 8, 15, 22, 29, 60, 90, 120, 180, 240, 300, and 365 for the 365-day

follow-up period; and days 8, 15, 22, 29, 60, 90, 120, 180, 240, 300, 360, 420, 480, 540, 600,

660, and 730 for the 730-day follow-up period. Moreover, to examine the effect of transmission

intensity, we set the population-level EIR at 0.1, 1, 10, or 100. To isolate the joint effect of the

rate of relapse and duration of follow-up across transmission intensities, we assumed

homogeneous biting.

Effect of Vector Control

The implementation of vector control measures may protect trial participants against mosquito

biting and reduce the number of reinfection events during follow-up. As a result, vector control

may reduce the bias due to frequent reinfection of trial participants at higher transmission

intensities.

To evaluate whether vector control measures are effective in reducing the bias in the

efficacy estimates, we simulated clinical trials under four different vector control scenarios: (1)

no vector control; (2) distribution of LLINs; (3) administration of IRS; and (4) distribution of

LLINs and administration of IRS. The extent to which LLINs and IRS prevent mosquito biting

depends upon the biting behavior of the mosquito population. We simulated different biting

behaviors by varying the proportion of bites that occurred while individuals were indoors (Φ_I)

and while individuals were in bed (Φ_B). We considered four biting behaviors: (1) endophagic

with no preference in biting time ($\Phi_I = 0.9$; $\Phi_B = 0.45$); (2) endophagic with nighttime biting

($\Phi_I = 0.9$; $\Phi_B = 0.675$); (3) endophagic with daytime biting ($\Phi_I = 0.9$; $\Phi_B = 0.225$); and (4)

exophagic with no preference in biting time ($\Phi_I = 0.1$; $\Phi_B = 0.05$). We simulated each

combination of vector control scenario and mosquito biting behavior at population-level EIRs of

0.1, 1, 10, and 100. By default, we assumed homogeneous biting.

Effect of Genotyping

Although vector control may decrease the bias by reducing the number of reinfection events, a

method capable of distinguishing relapses caused by hypnozoites acquired prior to treatment

from all other recurrent infections is needed to completely correct the bias in efficacy estimates.

Genotyping methods have been successfully used to determine the cause of each *P. vivax*

recurrent infection (12,33) and therefore could correct biases in phase-III clinical trials.

We evaluated the potential for a genotyping method at varying sensitivities and

specificities to correct the bias in the efficacy estimates. We considered a genotyping method

intended to distinguish relapses caused from hypnozoite batches acquired prior to treatment from

all other recurrent infections. Therefore, the sensitivity of the genotyping method was the

probability of correctly identifying a relapse caused by a hypnozoite batch acquired prior to

treatment, and the specificity of the genotyping method was the probability of correctly

identifying all other recurrent infections. We simulated clinical trials at population-level EIRs of

0.1, 1, 10, and 100, assuming homogeneous biting. We then analyzed the simulated outputs of

the clinical trials using a hypothetical genotyping method with sensitivities and specificities of

25%, 50%, 75%, or 100%.

Effect of the 8-aminoquinoline

By default, we simulated clinical trials for an 8-aminoquinoline with prophylactic effect lasting

28 days, consistent with treatment with chloroquine and primaquine. Under this assumption, the

duration of prophylaxis is less than the 32-day period of left-censoring, so the suppression of

blood-stage parasites during prophylaxis will not bias our efficacy estimates. Treatment with

tafenoquine when co-administered with chloroquine, however, provides prophylaxis for 45 days

and, therefore, may bias upwards our efficacy estimates (6).

To examine whether the duration of prophylaxis affects our estimates of efficacy, we

simulated and compared phase-III clinical trials for primaquine and tafenoquine with

prophylactic effects lasting 28 and 45 days, respectively. Because the benefit of prophylaxis may

vary with transmission intensity, we simulated each trial at population-level EIRs of 0.1, 1, 10,

and 100 with homogeneous biting.

Effect of the efficacy metric and infection endpoint

The combination of efficacy metric and infection endpoint used to calculate efficacy varied

across recent phase-III clinical trials (6–9). Different combinations of efficacy metrics and

infection endpoints could make comparison of efficacy estimates across different trials

challenging if efficacy estimates are sensitive to this feature of the trial design.

To test whether our efficacy estimates are sensitive to the choice of the efficacy metric

and the infection endpoint used, we simulated phase-III clinical trials at EIRs of 0.1, 1, 10, and

100 and calculated efficacy using different combinations of efficacy metrics and infection

endpoints. The efficacy metrics examined were the Cox proportional hazards model, incidence

rates, and the proportion at risk. The infection endpoints examined were PCR-detectable

recurrent infections, LM-detectable recurrent infections, and clinical recurrent infections.

Because we wanted to isolate the effect of the efficacy metric and the infection endpoint, we

simulated each trial assuming homogeneous biting.

Results

Figure S1. Comparison of efficacy metrics and infection types. *Efficacy estimates calculated*
using different methods and using different infection types with perfect genotyping are compared
across different entomological inoculation rates (EIR). The color of the point denotes the
recurrent infection endpoint used, where orange is PCR-detectable, red is LM-detectable, and
maroon is clinical. Because we assumed perfect genotyping, all infections were relapses caused
by hypnozoite batches acquired prior to 8-aminoquinoline treatment. Each point is the median of
200 simulations, and the bar is the interquartile range. The dotted line is the true clearance
probability simulated in each clinical trial.

Figure S2. Effect of vector control on efficacy estimates across different vector bionomics. The impact of LLIN distribution (red), IRS administration (green), and combined LLIN distribution and IRS administration (teal) on resolving biases in LM-detectable recurrence free efficacy estimates is compared to a no-intervention scenario (dark blue) across a range of entomological inoculation rates (EIR). Each point represents the median of 200 simulations, and each bar is the interquartile range. The dotted line is the clearance probability simulated in each trial. The absolute proportion of bites occurring indoors (Φ_I) and in bed (Φ_B) varied with (A) $\Phi_I = 0.9$ and $\Phi_B = 0.45$; (B) $\Phi_I = 0.9$ and $\Phi_B = 0.675$; (C) $\Phi_I = 0.9$ and $\Phi_B = 0.225$; and (D) $\Phi_I = 0.1$ and $\Phi_B = 0.05$

Figure S3. The effect of vector control measures on reducing reinfections across different
vector bionomics. The percentage of recurrent infections in the control arm that are treatment
failures (i.e., relapses arising from hypnozoites acquired prior to enrollment) is compared across
different entomological inoculation rates (EIR) and under different vector control scenarios.
Dark blue bars represent trials in which no vector control measures were provided, red bars are
trials in which LLINs were distributed, green bars are trials in which IRS was administered, and
teal bars are trials in which both LLINs and IRS were administered. The height of each bar is the
median of 200 simulations, and the segment is the interquartile range.

Figure S4. Comparison of "all-or-none" and "leaky" actions on efficacy estimates. LM-
detectable recurrence-free efficacy estimates obtained from simulated clinical trials are shown
for "all-or-none" (circles) and "leaky" (triangles) interventions at different entomological
inoculation rates (EIR) and levels of heterogeneity in biting. Each point represents the median of
200 simulations, and each bar is the interquartile range. The color represents the degree of
heterogeneity in individual-level exposure to mosquito biting with dark colors representing
greater heterogeneity. The dotted line is the clearance probability simulated in the trials.

Figure S5. Sample sizes necessary to achieve a specific level of power. *For a given EIR, the sample size in each arm is reported to achieve a specific level of power when calculating efficacy using (A) the Cox proportional hazards model, (B) incidence rates, and (C) the proportion at risk. Incidence rates were computed using the number of relapses caused by hypnozoites acquired prior to treatment in the control arm. Power calculations were performed for each of 200 simulations assuming homogeneous biting. The points and line denote the median sample size, and the shaded region is the interquartile range. Efficacy of the intervention was assumed to be 75%, the type-I error rate was set to 0.05, and the allocation ratio between trial arms was one.*

REFERENCES

1. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study. The Lancet. 2019 Jul;394(10195):332–43.

2. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends in Parasitology. 2020 Jun;36(6):560–70.

3. Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, et al. Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo. Sinnis P, editor. PLoS Negl Trop Dis. 2015 Mar 17;9(3):e0003595.

4. Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. The American Journal of Tropical Medicine and Hygiene. 2020 Sep 2;103(3):1094–9.

5. World Health Organization, Global Malaria Programme, World Health Organization. Control and elimination of plasmodium vivax malaria: a technical brief [Internet]. 2015 [cited 2020 Nov 17]. Available from: http://apps.who.int/iris/bitstream/10665/181162/1/9789241509244_eng.pdf?ua=1&ua=1

6. Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria. N Engl J Med. 2019 Jan 17;380(3):229–41.

7. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. The Lancet. 2014 Mar;383(9922):1049–58.

8. Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-Dose Tafenoquine to Prevent Relapse of *Plasmodium vivax* Malaria. N Engl J Med. 2019 Jan 17;380(3):215–28.

9. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. The Lancet. 2019 Sep;394(10202):929–38.

10. White MT, Walker P, Karl S, Hetzel MW, Freeman T, Waltmann A, et al. Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax. Nat Commun. 2018 Dec;9(1):3300.

11. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine Failure and Cytochrome P-450 2D6 in *Plasmodium vivax* Malaria. N Engl J Med. 2013 Oct 3;369(14):1381–2.

12. Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun. 2019 Dec;10(1):5595.

13. Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006 Dec;5(1):127.

14. Vynnycky E, Sumner T, Fielding KL, Lewis JJ, Cox AP, Hayes RJ, et al. Tuberculosis Control in South African Gold Mines: Mathematical Modeling of a Trial of Community-Wide Isoniazid Preventive Therapy. Am J Epidemiol. 2015 Apr 15;181(8):619–32.

15. WorldWide Antimalarial Resistance Network Methodology Study Group. Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis. Malar J. 2019 Jul 5;18(1):225.

16. Cooper L, Kang SY, Bisanzio D, Maxwell K, Rodriguez-Barraquer I, Greenhouse B, et al. Pareto rules for malaria super-spreaders and super-spreading. Nat Commun. 2019 Dec;10(1):3939.

17. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014 Dec;13(1):144.

18. Nekkab N, Lana R, Lacerda M, Obadia T, Siqueira AM, Monteiro WM, et al. Estimated impact of

tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study. PLoS
Medicine. 2021 Jan 6;

19.   Dahal P, Simpson JA, Dorsey G, Guérin PJ, Price RN, Stepniewska K. Statistical methods to derive
efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and
challenges. Malar J. 2017 Dec;16(1):430.

20.   Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of
chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial
Resistance Network systematic review and individual patient pooled meta-analysis. The Lancet
Infectious Diseases. 2018 Sep;18(9):1025–34.

21.   Pollard EJM, MacLaren D, Russell TL, Burkot TR. Protecting the peri-domestic environment: the
challenge for eliminating residual malaria. Sci Rep. 2020 Dec;10(1):7018.

22.   Monroe A, Moore S, Okumu F, Kiware S, Lobo NF, Koenker H, et al. Methods and indicators for
measuring patterns of human exposure to malaria vectors. Malar J. 2020 Dec;19(1):207.

23.   Moreno JE, Rubio-Palis Y, Páez E, Pérez E, Sánchez V. Abundance, biting behaviour and parous
rate of anopheline mosquito species in relation to malaria incidence in gold-mining areas of
southern Venezuela. Medical and Veterinary Entomology. 2007 Dec 18;21(4):339–49.

24.   Paul MR, Grenfell BT, Hoti SL, Ramaiah KD, Bundy DA, Das PK, et al. Quantifying mosquito
biting patterns on humans by DNA fingerprinting of bloodmeals. The American Journal of Tropical
Medicine and Hygiene. 2001 Dec 1;65(6):722–8.

25.   Guelbéogo WM, Gonçalves BP, Grignard L, Bradley J, Serme SS, Hellewell J, et al. Variation in
natural exposure to anopheles mosquitoes and its effects on malaria transmission. eLife. 2018 Jan
23;7:e32625.

26.   Liebman KA, Stoddard ST, Reiner RC, Perkins TA, Astete H, Sihuincha M, et al. Determinants of
Heterogeneous Blood Feeding Patterns by Aedes aegypti in Iquitos, Peru. Barrera R, editor. PLoS
Negl Trop Dis. 2014 Feb 13;8(2):e2702.

27.   Sagna AB, Kibria MG, Naher S, Islam S, Aktaruzzaman MM, Alam MS, et al. Stratifying malaria
receptivity in Bangladesh using archived rapid diagnostic tests. Malar J. 2020 Sep 23;19(1):345.

28.   Poinsignon A, Cornelie S, Ba F, Boulanger D, Sow C, Rossignol M, et al. Human IgG response to a
salivary peptide, gSG6-P1, as a new immuno-epidemiological tool for evaluating low-level
exposure to Anopheles bites. Malar J. 2009 Aug 13;8:198.

29.   Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of
Plasmodium vivax Infection Usually Result from Activation of Heterologous Hypnozoites. J
INFECT DIS. 2007 Apr;195(7):927–33.

30.   Imwong M, Boel ME, Pagornrat W, Pimanpanarak M, McGready R, Day NPJ, et al. The First
Plasmodium vivax Relapses of Life Are Usually Genetically Homologous. The Journal of Infectious
Diseases. 2012 Feb 15;205(4):680–3.

31.   Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, et al. Evaluation of *Plasmodium vivax*
Genotyping Markers for Molecular Monitoring in Clinical Trials. J INFECT DIS. 2009
Apr;199(7):1074–80.

32.   Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, et al. Development of
amplicon deep sequencing markers and data analysis pipeline for genotyping multi-clonal malaria
infections. BMC Genomics. 2017 Dec;18(1):864.

33.   Lin JT, Hathaway NJ, Saunders DL, Lon C, Balasubramanian S, Kharabora O, et al. Using
Amplicon Deep Sequencing to Detect Genetic Signatures of *Plasmodium vivax* Relapse. J Infect
Dis. 2015 Sep 15;212(6):999–1008.

34.   Shanks GD, White NJ. The activation of vivax malaria hypnozoites by infectious diseases. The
Lancet Infectious Diseases. 2013 Oct;13(10):900–6.

35.   Mandal S, Sarkar R, Sinha S. Mathematical models of malaria - a review. Malar J. 2011;10(1):202.

36.   Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al. Reducing
Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention
Strategies. Krishna S, editor. PLoS Med. 2010 Aug 10;7(8):e1000324.

37.   Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, et al. Simulations for
972   designing and interpreting intervention trials in infectious diseases. BMC Med. 2017 Dec;15(1):223.
973   38.   Smith DL, Battle KE, Hay SI, Barker CM, Scott TW, McKenzie FE. Ross, Macdonald, and a
974   Theory for the Dynamics and Control of Mosquito-Transmitted Pathogens. Chitnis CE, editor. PLoS
975   Pathog. 2012 Apr 5;8(4):e1002588.
976   39.   Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the
977   knowledge of Plasmodium vivax, a neglected human malaria parasite. The Lancet Infectious
978   Diseases. 2009 Sep;9(9):555–66.
979   40.   Halloran ME, Haber M, Longini IM. Interpretation and Estimation of Vaccine Efficacy under
980   Heterogeneity. American Journal of Epidemiology. 1992 Aug 1;136(3):328–43.
981   41.   Smith PG, Rodrigues LC, Fine PEM. Assessment of the Protective Efficacy of Vaccines against
982   Common Diseases Using Case-Control and Cohort Studies. Int J Epidemiol. 1984;13(1):87–93.
983   42.   White MT, Griffin JT, Drakeley CJ, Ghani AC. Heterogeneity in malaria exposure and vaccine
984   response: implications for the interpretation of vaccine efficacy trials. Malar J. 2010 Dec;9(1):82.
985   43.   Gaedigk A, Dinh JC, Jeong H, Prasad B, Leeder JS. Ten Years' Experience with the CYP2D6
986   Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision
987   Therapeutics. J Pers Med. 2018 Apr 17;8(2).
988   44.   Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a Novel
989   Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative
990   Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient. Am J Trop Med
991   Hyg. 2019;100(1):213–21.
992   45.   Halloran ME, Longini IM, Struchiner CJ. Design and Analysis of Vaccine Studies [Internet]. New
993   York, NY: Springer New York; 2010 [cited 2020 Oct 25]. (Statistics for Biology and Health).
994   Available from: http://link.springer.com/10.1007/978-0-387-68636-3
995   46.   Carnevale P, Frézil JL, Bosseno MF, Le Pont F, Lancien J. [The aggressiveness of Anopheles
996   gambiae A in relation to the age and sex of the human subjects]. Bull World Health Organ.
997   1978;56(1):147–54.
998   47.   Port GR, Boreham PFL, Bryan JH. The relationship of host size to feeding by mosquitoes of the
999   *Anopheles gambiae* Giles complex (Diptera: Culicidae). Bull Entomol Res. 1980 Mar;70(1):133–44.
48.   Herrera S, Solarte Y, Jordán-Villegas A, Echavarría JF, Rocha L, Palacios R, et al. Consistent safety
and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human
volunteers. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4–11.
49.   Kiattibutr K, Roobsoong W, Sriwichai P, Saeseu T, Rachaphaew N, Suansomjit C, et al. Infectivity
of symptomatic and asymptomatic Plasmodium vivax infections to a Southeast Asian vector,
Anopheles dirus. Int J Parasitol. 2017;47(2–3):163–70.
50.   White MT, Griffin JT, Churcher TS, Ferguson NM, Basáñez M-G, Ghani AC. Modelling the impact
of vector control interventions on Anopheles gambiae population dynamics. Parasites Vectors. 2011
Dec;4(1):153.
51.   Schoenfeld DA. Sample-Size Formula for the Proportional-Hazards Regression Model. Biometrics.
1983 Jun;39(2):499.
52.   Smith PG, Morrow RH, Ross DA, International Epidemiological Association, Wellcome Trust
(London, England), editors. Field trials of health interventions: a toolbox. 3rd edition. Oxford:
Oxford University Press; 2015. 444 p.